Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Artemis Medicare Services Ltd

ARTEMISMED
NSE
239.87
0.39%
Last Updated:
29 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

Artemis Medicare Services Ltd

ARTEMISMED
NSE
239.87
0.39%
29 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
3,797Cr
Close
Close Price
239.87
Industry
Industry
Hospitals
PE
Price To Earnings
39.13
PS
Price To Sales
3.64
Revenue
Revenue
1,042Cr
Rev Gr TTM
Revenue Growth TTM
12.97%
PAT Gr TTM
PAT Growth TTM
31.00%
Peer Comparison
How does ARTEMISMED stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
ARTEMISMED
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
195210225219225223241232240255275272
Growth YoY
Revenue Growth YoY%
30.725.320.016.715.36.57.36.26.514.213.817.2
Expenses
ExpensesCr
170182191186187187199195204214224228
Operating Profit
Operating ProfitCr
262834333836423736415145
OPM
OPM%
13.113.315.214.916.916.217.516.115.016.218.416.4
Other Income
Other IncomeCr
2122247912784
Interest Expense
Interest ExpenseCr
578898888777
Depreciation
DepreciationCr
9910101111111112111212
PBT
PBTCr
141319162022312729303930
Tax
TaxCr
335565866998
PAT
PATCr
111014121417222123213022
Growth YoY
PAT Growth YoY%
-18.917.954.412.533.569.463.478.360.328.335.67.9
NPM
NPM%
5.54.76.05.36.37.49.28.99.68.310.98.2
EPS
EPS
0.80.71.00.81.01.11.41.31.51.41.91.4

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
5475654085557378799371,042
Growth
Revenue Growth%
3.4-27.735.932.919.16.611.2
Expenses
ExpensesCr
483504373487643746785869
Operating Profit
Operating ProfitCr
6461356794133152172
OPM
OPM%
11.710.98.612.212.715.116.216.6
Other Income
Other IncomeCr
4574773331
Interest Expense
Interest ExpenseCr
1113131220313229
Depreciation
DepreciationCr
2023222231404547
PBT
PBTCr
37318375168108128
Tax
TaxCr
16111613192531
PAT
PATCr
201963138498296
Growth
PAT Growth%
-4.5-68.3409.821.129.367.217.3
NPM
NPM%
3.73.41.55.75.25.68.89.3
EPS
EPS
15.51.50.52.42.93.65.46.1

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
1313131313141414
Reserves
ReservesCr
280300307346390435824869
Current Liabilities
Current LiabilitiesCr
177158118138206185216247
Non Current Liabilities
Non Current LiabilitiesCr
84115160210291332298290
Total Liabilities
Total LiabilitiesCr
5545866007109059721,3571,426
Current Assets
Current AssetsCr
113118109127170180539521
Non Current Assets
Non Current AssetsCr
442469491583735791819905
Total Assets
Total AssetsCr
5545866007109059721,3571,426

Cash Flow

Consolidated
Standalone
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
40562760127109146
Investing Cash Flow
Investing Cash FlowCr
-50-26-37-107-158-88-385
Financing Cash Flow
Financing Cash FlowCr
14-27184438-29267
Net Cash Flow
Net Cash FlowCr
528-37-827
Free Cash Flow
Free Cash FlowCr
-1730-4-49-183755
CFO To PAT
CFO To PAT%
198.4288.2442.5189.6334.5221.5177.2
CFO To EBITDA
CFO To EBITDA%
63.491.377.588.3135.382.095.9

Ratios

Consolidated
Standalone
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
01832946089132,3073,781
Price To Earnings
Price To Earnings
0.09.245.319.123.646.945.8
Price To Sales
Price To Sales
0.00.30.71.11.22.64.0
Price To Book
Price To Book
0.00.71.22.12.76.14.9
EV To EBITDA
EV To EBITDA
1.24.211.611.612.219.324.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
99.8100.499.8100.0100.0100.0100.0
OPM
OPM%
11.710.98.612.212.715.116.2
NPM
NPM%
3.73.41.55.75.25.68.8
ROCE
ROCE%
12.410.74.48.810.213.012.4
ROE
ROE%
7.06.21.98.79.411.09.8
ROA
ROA%
3.73.31.04.44.25.16.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Overview** Artemis Medicare Services Ltd, launched in July 2007 by the promoters of the Apollo Tyres Group (who hold ~67% ownership), is a leading integrated healthcare provider in India. The company operates a 700+ bed quaternary care, super-specialty hospital in Gurugram (Delhi NCR), recognized as the first in the city to achieve both **Joint Commission International (JCI)** and **NABH** accreditation. Artemis has established itself as a premier destination for high-quality, globally benchmarked medical care, serving a diverse patient base—including over 100 countries for medical value travel. --- ### **Core Operations & Infrastructure** - **Flagship Facility**: The multi-specialty hospital in Gurugram currently operates over **700 beds** across three towers, following phased commissioning of the third tower in FY25. - **Centers of Excellence**: 14 dedicated CoEs across 40+ medical specialties, including Oncology, Cardiology, Neurology, Orthopaedics, and Gastroenterology. - **Technology & Innovation**: - Partnered with **KIMS, Hyderabad** to offer heart-lung transplant services. - Launched India’s first private **Geriatrics & Longevity Department**. - Strategic collaboration with **Abhinav Bindra Targeting Performance (ABTP)** for AI-driven, personalized physiotherapy and rehabilitation. - Upgrading its **Hospital Information System (HIS)** and integrating **AI** for clinical decision-making, precision medicine, diagnostics, and patient engagement. --- ### **Expansion Strategy: Domestic & International** #### **Raipur Expansion (Central India)** - A **300+ bed super-specialty hospital** in **Raipur, Chhattisgarh**, is on track to become operational by **March 2026**. - Key specialties include Cardiology, Oncology, Neurology, and Orthopaedics, with a built-up area of **270,000 sq ft** across two basements, ground, and six upper floors. - **Long-term O&M and Medical Services Agreement** signed; construction is nearly complete, with interior work commencing soon. - **Financial Impact**: Management expects significant uplift in **top line, EBITDA, and EPS within 1.5 years** of launch. - **Revenue Outlook**: Initial **ARPOB (Average Revenue Per Occupied Bed)** is expected at ₹35,000–38,000, targeted to grow to ₹45,000 and eventually ₹60,000. - **Competitive Edge**: Superior infrastructure and strong partnerships with renowned physicians Dr. Agarwal and Dr. Gupta to drive patient inflow. #### **Gurugram Capacity Expansion** - Expansion is occupancy-linked: additional beds will be added within ~one quarter once occupancy reaches **70%**. - Plans to add **100+ beds** immediately and pursue enhanced **Floor Area Ratio (FAR)** approvals for **200 more beds** in the future. - Addition of new towers improving **unit economics**, **economies of scale**, and **operational efficiency**. #### **Delhi NCR Rebuild** - Planning to reconstruct its **Delhi hospital** into a **650-bed state-of-the-art facility**. - Execution subject to fulfillment of **conditions precedent in a binding MoU**, expected by **end-December 2025**. - Timeline: Prioritize **Raipur breakeven**, followed by Delhi operations, then Gurugram expansion. #### **Asset-Light Network Growth** - **Hub-and-Spoke Model**: Smaller facilities — *Artemis Lite* and *Daffodils by Artemis* — act as referral centers for the Gurugram flagship. - **Artemis Lite**: Neighborhood multi-specialty centers expanding in Tier 1 and 2 cities. - **Daffodils by Artemis**: Premium maternity and child-care centers with surgical capabilities; currently 3 operational, with positive patient traction. - New **~100-bed dedicated children’s hospital** planned in Haryana (Delhi NCR), expected in FY25 under an asset-light model. #### **International Expansion** - **Artemis Curepipe Hospital**, an 80-bed facility in **Mauritius**, became operational in FY24. - First of two planned hospitals; second to follow under an O&M agreement. - Strategic entry into **North India** via a MoU with **Dr. Vidya Sagar Kaushalya Devi Memorial Health Centre**. - Exploring further overseas markets for scalable healthcare delivery models. --- ### **Joint Ventures & Strategic Partnerships** - **Artemis Cardiac Care (JV with Philips Medical Systems Netherlands BV)**: - Network of **300+ cardiac centers** planned across India. - Currently operates **8–9 centers**, with plans to open **3–5 new centers annually**. - Targets 25–50 centers within 3–4 years; already served **50,000+ patients**. - Centers located in Tier 2 and Tier 3 cities, offering affordable, high-quality cardiac care. - New unit in **Chennai** scheduled for Q1 FY24. --- ### **Financial & Operational Highlights (As of Nov 2025)** - **Record Financial Performance**: Highest-ever **ARPOB** and strong **EBITDA margins** achieved in recent quarters, driven by improved case/payer mix and scale. - **Bed Capacity Growth**: ~20% YoY increase in operational bed count contributing to temporary dip in occupancy %, but **absolute occupied bed numbers continue to rise**. - **Revenue Mix**: ~30% of revenue from **international patients**, underscoring Artemis’ global reputation in **medical value travel**. --- ### **Funding & Capital Raise** - **Jul 2025 / Aug 2024**: Raised **₹330 crores** (~$39M USD) from **International Finance Corporation (IFC)** via **compulsorily convertible debentures (CCDs)**. - **Purpose**: Fund **quaternary and super-specialty care expansion** across Delhi NCR and Tier 2 cities (greenfield and brownfield projects). - Capital supports both **asset-heavy** (hospitals) and **asset-light** (Lite, Daffodils, Cardiac) growth models. --- ### **Key Strengths** - **Brand & Accreditation**: First JCI-accredited hospital in Gurugram; trusted by international patients and corporates. - **Strategic Alliances**: Partnerships with over **100 corporates**, Philips, KIMS, IFC, and ABTP. - **Doctor & Talent Attraction**: Strong brand equity attracts leading specialists. - **Multi-Pronged Growth Strategy**: Combination of **flagship scaling, hub-and-spoke model, JVs, and global expansion**. - **Financial Discipline**: Focus on unit economics, margin improvement, and capital efficiency. ---